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Abstract: Hendra and Nipah viruses are related emergent paramyxoviruses that infect and cause disease in animals and 
humans. Disease manifests as a generalized vasculitis affecting multiple organs, but is the most severe in the respiratory 
and central nervous systems. The high case fatality and person-to-person transmission associated with the most recent 
NiV outbreaks, and the recent re-emergence of HeV, emphasize the importance and necessity of effective therapeutics for 
these novel agents. In recent years henipavirus research has revealed a more complete understanding of pathogenesis and, 
as a consequence, viable approaches towards vaccines and therapeutics have emerged. All strategies target early steps in 
viral replication including receptor binding and membrane fusion. Animal models have been developed, some of which 
may prove more valuable than others for evaluating the efficacy of therapeutic agents and regimes. Assessments of pro-
tective host immunity and drug pharmacokinetics will be crucial to the further advancement of therapeutic compounds. 
INTRODUCTION 
  Hendra virus (HeV) and Nipah virus (NiV) are closely 
related highly pathogenic paramyxoviruses that have 
emerged independently in the past 15 years and continue to 
emerge in new locations. Flying foxes in the genus Pteropus 
are considered to be the natural reservoir for both viruses as 
demonstrated by seroconversion and isolation of HeV- and 
NiV-like viruses from bat tissues and secretions [1, 2]. Addi-
tionally, extensive serological surveys have not demon-
strated the presence of HeV- or NiV-specific antibodies in 
other species. Indeed the flying fox geographic range en-
compasses all locations where HeV and NiV have been 
found. Paramyxoviruses are large, enveloped, negative-sense 
ssRNA viruses, and include such well-known members as 
measles virus (MeV), simian virus 5 (SV5), and respiratory 
syncytial virus (RSV) [3]. It is a diverse virus family, with 
various members causing common upper and lower respira-
tory tract infections to less common manifestations of neuro-
logical disease. In contrast, NiV and HeV are distinguished 
from all other paramyxoviruses most notably by their broad 
species tropism and high case fatality, and they have been 
classified into the new Henipavirus genus within the family 
Paramyxoviridae [4]. HeV has appeared sporadically in Aus-
tralia since 1994 where infection has been transmitted from 
horses to humans (reviewed in [5]). Presumably horses be-
come infected through spillover events from flying foxes, 
although no virus has been isolated from flying foxes during 
outbreaks. In horses, the disease presented as a severe respi-
ratory infection, while one of the two reported human mor-
talities had severe respiratory disease, and the other suc-
cumbed to encephalitis 13 months following the presumed 
time of exposure. Recent outbreaks where horse fatalities 
were documented include 1999, 2004 and 2006 and although 
no human mortalities have occurred, one mildly ill, sero-
converting, human case has been reported [6-8]. NiV first 
appeared in peninsular Malaysia and Singapore in 1998-9   
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and the majority of infections occurred in pigs with subse-
quent transmission to humans (reviewed in [9, 10]). In pigs, 
infection was largely subclinical; however, where clinical 
disease was observed, it manifested as respiratory and en-
cephalitic disease with low fatality ratios for respiratory 
cases. In contrast, humans developed severe febrile encepha-
litis with high case fatality and up to 25% of NiV cases also 
exhibited respiratory signs including non-productive cough. 
Interestingly, both relapsing and late-onset encephalitis syn-
dromes with significant fatality (~18%) have been recog-
nized following either acute NiV encephalitic episodes or 
non-encephalitic/ asymptomatic infection. NiV has re-
emerged numerous times since 1998: twice in 2001 in Bang-
ladesh and West Bengal India, again in 2003 in Bangladesh, 
three times in Bangladesh in 2004 and 2005, and most re-
cently in 2007 in Nadia, India [11-15]. Significant observa-
tions in all of the Bangladesh and Indian NiV outbreaks have 
included a higher incidence of acute respiratory distress syn-
drome in conjunction with encephalitis, epidemiological 
findings consistent with person-to-person transmission [16], 
and higher case fatality ratios (~75%). Furthermore, no in-
termediate or amplification host has been identified and di-
rect transmission of NiV from the reservoir host to humans 
has been suggested. In West Bengal in 2001 there was no 
concurrent illness in animals and in Bangladesh in 2004 the 
common epidemiological link among cases was drinking 
fresh date palm sap [12, 17]. In general, it is believed that 
date palm sap is regularly contaminated by flying foxes and 
their excretions. 
  NiV and HeV are classified as zoonotic biosafety level 4 
(BSL-4) viruses and infectious virus can only be studied at a 
handful of laboratories worldwide. Both viruses have also 
been included among the various pathogenic agents of biode-
fense concern and each are classified as priority pathogens in 
category C by the Centers for Disease Control and Preven-
tion (CDC) and the National Institute of Allergy and Infec-
tious Diseases (NIAID). The category C agents include high 
emerging pathogens with the potential for causing morbidity 
and mortality with major economic and health impacts. 
Henipaviruses in particular, could be engineered for mass 
dissemination because of their availability from natural 
sources and their relative ease of propagation and dissemina-15    The Open Virology Journal, 2007, Volume 1  Bossart et al. 
tion. Currently there are no specific antiviral therapies or 
vaccines available for treating or preventing NiV or HeV 
infection resulting from a natural outbreak, laboratory acci-
dent or deliberate misuse. 
PATHOGENESIS IN HUMANS 
  There have been two fatal cases of HeV infection in hu-
mans, the first presented with severe respiratory disease and 
upon autopsy the patient’s lungs had gross lesions of conges-
tion, hemorrhage and edema associated with chronic alveoli-
tis and syncytial cell formation. The second fatal case pre-
sented thirteen months post-exposure and exhibited lepto-
meningitis with lymphocytes and plasma cells and foci of 
necrosis in various parts of the brain parenchyma (reviewed 
in [18]). Multinucleate endothelial cells were also present in 
the viscera as well as in the brain. During the first NiV out-
break in Malaysia encephalitis killed 105 of 265 infected 
individuals [19]. Immuno- and histological features were 
described as a systemic endothelial infection accompanied 
by vasculitis, thrombosis, ischaemia and necrosis [20]. These 
changes were especially noted in the central nervous system 
(CNS). Immunohistochemical analyses demonstrated the 
widespread presence of NiV antigens both in neurons and 
other parenchymal cells in necrotic foci in the CNS and in 
endothelial cells of affected blood vessels. Evidence of vas-
culitis and endothelial infection was also seen in most organs 
examined. Disseminated endothelial cell infection, vasculitis, 
thrombosis and CNS parenchymal cell infection all appear to 
play essential roles in the fatal outcome of human NiV infec-
tion [18, 20]. In the more recent NiV outbreaks in India and 
Bangladesh, similar clinical signs were noted. However, a 
higher incidence of acute respiratory distress syndrome in 
conjunction with encephalitis was also described [11, 12]. 
VIRUS ENTRY INTO HOST CELLS 
  Paramyxoviruses contain two major membrane-anchored 
envelope glycoproteins that are required for infection of a 
receptive host cell. All members contain an attachment gly-
coprotein, which binds the host cell receptor, while the sec-
ond is the fusion (F) glycoprotein, which mediates pH-
independent membrane fusion between the virus and its host 
cell (reviewed in [3]). Following virus attachment to a per-
missive host cell, paramyxovirus mediated membrane fusion 
occurs at neutral pH resulting in delivery of the nucleocapsid 
into the cytoplasm of the host cell. Most paramyxovirus at-
tachment glycoproteins possess hemagglutinin and 
neuraminidase activities (HN), which bind sialic acid moie-
ties. Virion attachment most likely occurs through binding of 
multiple sialic acid-expressing proteins on the cell surface. 
The morbillivirus attachment glycoproteins (H) contain only 
hemagglutinin activity and do not bind sialic acid. Three 
morbilliviruses, measles virus, canine distemper virus and 
rinderpest virus, can employ cell-surface proteins as viral 
receptors [21-26]. HeV and NiV possess attachment glyco-
proteins (G) that lack hemagglutinin and neuraminidase ac-
tivities and are the only other paramyxoviruses known to 
utilize host cell proteins that do not contain sialic acid as 
viral receptors. Specifically, ephrin-B2 ligand was identified 
as a receptor utilized by HeV and NiV for infection [27, 28] 
and subsequently, ephrin-B3 ligand was identified as an al-
ternate receptor for NiV [29]. Ephrin molecules are members 
of a family of receptor tyrosine kinase ligands and are highly 
conserved across vertebrate species [30, 31]. Ephrin ligands 
and their receptors play important roles in regulation of tis-
sue assembly and cell migration [30] and are critical to brain 
function, neuronal networking and morphogenesis [32]. Eph-
rin-B2 ligand is an artery-specific protein that mediates 
blood vessel development and maturation [33, 34]. Neurons 
smooth muscle, arterial endothelial cells and capillaries all 
exhibit high levels of ephrin-B2 ligand expression consistent 
with the known tissue tropism of HeV and NiV in vivo. 
Ephrin-B3 ligand is expressed in certain neural subsets and 
may play an important role in HeV and NiV infection in the 
CNS. All paramyxoviruses F glycoproteins, including HeV 
and NiV, are typical class I fusion proteins that utilize two 
internal heptad repeats to mediate membrane merger (re-
viewed in [35]). Because both attachment and fusion are 
critical steps for productive infection, molecules that inter-
fere with either process represent potential antiviral agents 
and in fact the most extensively characterized novel thera-
peutics fall within this category as will be discussed below. 
ANIMAL MODELS 
  HeV and NiV are currently classified as BSL-4 agents 
and consequently human efficacy studies for testing potential 
therapeutic products are not easily achievable. In 2002, the 
U.S. Food and Drug Administration (FDA) implemented the 
Animal Efficacy Rule for the development of therapeutic 
products under these circumstances. Specifically, FDA can 
rely on evidence derived from animal studies in the evalua-
tion of product effectiveness when particular criteria are met, 
such as a well-understood mechanism for both the patho-
genicity of the agent and the underlying mode of action of 
the product. Importantly, the therapeutic effect must also be 
demonstrated in more than one animal species. Once these 
criteria have been met, human clinical trials could com-
mence, most likely in populations at high risk of natural in-
fection by HeV and NiV. 
  A strong epidemiological association existed in Malaysia 
between human NiV infection and close direct contact with 
pigs, especially sick and dying animals. No direct association 
with flying foxes was made. An epidemiological link has 
been noted between HeV infection in people and horses dy-
ing from HeV disease. Again, neither HeV disease nor sero-
conversion has ever been identified in wildlife carers who 
came into close and regular contact with sick and injured 
bats. While both horses and pigs have been experimentally 
infected with HeV and NiV, respectively [42, 44], neither 
represents a practical option for multiple experimental effi-
cacy studies. Large animals such as horses are difficult to 
manage in sufficient numbers under BSL-4 conditions and in 
pigs NiV infection is mostly inconsequential from a clinical 
perspective. For the purposes of this review we will focus on 
the smaller animal model systems that have been explored 
(Table 1). There was no serological evidence of NiV infec-
tion in rodents in Malaysia [9, 45]. However, attempts were 
made to infect mice experimentally. NiV and HeV do not 
cause disease in mice after subcutaneous administration 
(5,000 TCID50 HeV) (Crameri, G and Eaton, B.T., unpub-
lished observations) or with either an intranasal (6x10
5 pfu 
NiV) or intraperitoneal (10
7 pfu NiV) challenge of NiV [40], 
although the HeV is lethal if administered intracranially. 
Rabbits are not susceptible to HeV associated disease when  
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Table 1.  Small Animal Models for Henipavirus Infection 
 
Challenge Dose  Pathology 
  Intra-
Peritoneal 
Subcutaneous  Intranasal-Oral-
Oronasal 
General Lung  Brain 
Ref. 
Guinea 
pig 
HeV 
 
5,000 TCID50 
50,000 TCID50 
 
Weakness, lethargy, 
abortion, head tilt. Death 
or euthanasia 6-15 days 
PI. Vascular degenera-
tion in multiple organs. 
Immuno-staining of 
blood vessels. 
Fibrinoid degenera-
tion of blood ves-
sels, syncytia of 
endothelium and 
alveolar walls 
microscopical 
lesions of 
encephalitis in 
8/15 guinea-
pigs subcuta-
neously inocu-
lated with 
30,000-50,000 
TCID50 
[36-38] 
Guinea 
pig 
NiV 
50,000 TCID50    
Mild behavioral 
changes, ataxia. Eutha-
nasia 7 – 10 DPI. Infec-
tion in 3/8 animals. 
Vasculitis, fibrinoid 
necrosis of vessels in 
multiple organs, 
oophoritis, endometrial 
necrosis. Antigen in 
endothelium, syncytia, 
blood vessel walls, 
myometrium and endo-
metrium. 
Lung lesions not 
observed 
Encephalitis 
not observed  [39] 
Golden 
Hamster 
NiV 
100 – 10,000 
pfu    1000 – 1,000,000 
pfu 
Tremors, paralysis, 
lethargy, breathing 
difficulty. Death 9 – 29 
DPI. Vascular fibrinoid 
necrosis and inflamma-
tion in multiple organs. 
Antigen and genome in 
endothelial cells, syn-
cytia and tunica media 
of blood vessels. 
Paranchymal in-
flammation, vascu-
litis 
** 
Vasculitis. 
Mild inflam-
mation of 
parenchyma 
and meninges. 
Antigen, ge-
nome and 
inclusion bod-
ies in neurons 
** 
[40] 
Cat 
HeV 
 5,000  TCID50 50,000  TCID50 
Death or euthanasia 6-7 
DPI. Vascular lesions 
and paranchymal degen-
eration in gastrointesti-
nal tract and lymphoid 
organs. 
Interstitial pneu-
monia, vascular 
necrosis, endothe-
lial syncytia. 
** 
Encephalitis 
not reported 
 
[36, 41] 
Cat 
NiV   500  TCID50 50,000  TCID50 
Euthanasia 7-9 DPI after 
short febrile illness and 
increase in respiratory 
rate; clinical resolution 
in one cat. Necrosis in 
spleen, inflammation of 
bladder, necrotizing 
lymphadenitis. 
Focal necrotizing 
alveolitis with 
syncytia, bronchio-
litis, fibrinoid ne-
crosis of blood 
vessel walls, endo-
thelial syncytia. 
Antigen in affected 
bronchial and al-
veolar epithelium, 
syncytia and blood 
vessels. 
** 
Meningitis, 
meningeal 
vasculitis with 
endothelial 
syncytia; dis-
tinct encephali-
tis has not been 
identified 
[42, 43] 
Ferret 
NiV*     500-50,000  TCID50 
Fever, depression and 
weakness. Euthanasia 6 
– 10 DPI following 1 – 2 
days fever. Vascular 
fibrinoid necrosis in 
multiple organs, necro-
tising alveolitis, syncytia 
of endothelium and 
alveolar epithelium, 
necrotizing lymphadeni-
tis. Antigen in blood 
vessel walls and syn-
cytia. 
Vascular fibrinoid 
necrosis, necrotis-
ing alveolitis, syn-
cytia of alveolar 
epithelium. Anti-
gen in blood vessel 
walls and syncytia. 
** 
Not yet deter-
mined 
Unpub-
lished 
(Bos-
sart, K, 
Bing-
ham, J, 
and 
Middle-
ton, D) 
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challenged subcutaneously (5,000 TCID50 HeV) [46]. 
Guinea pigs were experimentally infected with HeV soon 
after its discovery (5,000-50,000 TCID50 HeV) [46] and de-
veloped generalized vasculitis affecting lung, kidney, spleen, 
lymph nodes, gastrointestinal tract, and skeletal and intercos-
tal muscles [36, 38]. However, in spite of vascular involve-
ment of the lung, there was little or no pulmonary edema. 
NiV infection in the guinea pig (50,000 TCID50 NiV) clini-
cally manifested as ruffled fur and abnormal (less fearful) 
behavior [39] with gross pathology limited to edema of the 
mesentery, broad ligament, and retroperitoneal tissues. Sig-
nificant microscopic pathology included vasculitis with fi-
brinoid necrosis and endothelial syncytial cell formation in 
the myocardium, kidney, lymph node, spleen, myometrium, 
retroperitoneal tissues, and submucosal vessels of the blad-
der. Oophoritis and the presence of hemorrhagic corpora 
lutea were also noted together with endometrial degeneration 
and necrosis accompanied by multinucleated cells. 
  A golden hamster animal model for acute NiV virus in-
fection has been established where, importantly, encephalitis 
and neuron infection were demonstrated similar to those seen 
in NiV-infected humans [40].
 The LD50 values for hamsters 
inoculated by intraperitoneal
 and intranasal routes were 270 
pfu and 47,000 pfu, respectively. Notably, the brain was the 
most severely affected organ in terms of vascular
 and paren-
chymal lesions. Neurons in the vicinity of vascultis showed 
numerous cytoplasmic eosinophilic inclusion bodies and 
both viral antigen and RNA were found extensively through-
out neurons. Ultrastructural analysis revealed cytoplasmic 
inclusions composed of
  defined herringbone nucleocapsids 
typical of paramyxoviruses. However, although HeV and 
NiV clearly cause systemic disease in humans, NiV was not 
detected in serum samples from infected hamsters. Moreo-
ver, the pathology seen in the lungs and kidneys of NiV-
infected hamsters differed from that seen in HeV-infected 
horses and NiV-infected humans. HeV infection of hamsters 
has not been reported. 
  Experimental HeV infection of cats has been performed 
and findings from those studies were similar to those of 
horses and humans, namely generalized vascular disease 
with the most severe effects seen in the lung [36, 44]. NiV 
infection in cats was comparable to that observed with HeV 
except that with NiV there was also extensive inflammation 
of the upper and lower respiratory tract epithelium, associ-
ated with the presence of viral antigen [42], similar to the 
severe respiratory disease observed in humans in the recent 
NiV outbreaks in Bangladesh. Cats succumb to infection 6 to 
10 days following parenteral inoculation of as low as 500 
TCID50 NiV [43], or oronasal administration of 50,000, 
TCID50 of low passage, plaque purified HeV [41, 42, 46] or 
NiV (Bossart, K., Bingham, J. and Middleton, D., unpub-
lished data). Gross pathology common to both HeV and NiV 
infection of cats consisted of hydrothorax, dense purple-red 
consolidation in the lung with fluid accumulation and froth 
in the bronchi (reviewed in [18]. Histologically cats infected 
with NiV develop a necrotizing alveolitis, with necrotic foci 
developing within a range of other organs, particularly kid-
ney, spleen, lymph nodes, bladder, ovaries, adrenal and men-
inges. Studies on cats that were euthanized early in the 
course of the infection (1 day after the onset of fever, as de-
termined by radiotelemetry measurement of body tempera-
ture) indicated that alveolar infection by NiV preceded vas-
cular infection suggesting an increased tropism for alveolar 
epithelium as compared to vascular tissue (Bingham, J., un-
published observation). Thus evidence to date indicates that 
the cat represents an animal model in which henipavirus in-
duced pathology closely resembles the lethal respiratory dis-
ease caused by HeV and NiV in humans. 
  Experimental NiV infection in Pteropid bats has been 
attempted [39]. All bats that were challenged with 50,000 
TCID50 NiV remained clinically well throughout the study 
period and no febrile responses were recorded following NiV 
inoculation via a parenteral route. Challenged bats developed 
a sub-clinical infection characterized by episodic viral shed-
ding in urine, limited presence of virus within selected vis-
cera and seroconversion. No gross abnormalities were identi-
fied on post-mortem examination of animals at various times 
post exposure; all bat tissues were negative upon immuno-
histochemical labeling for NiV antigen. 
  Recently, we have been evaluating the potential of the 
ferret as an improved animal model for NiV infection. Fer-
rets have emerged as important animal models for several 
major respiratory diseases including highly pathogenic avian 
influenza [47], severe acute respiratory syndrome (SARS) 
[48], and also morbilliviruses [49], the closest relatives to 
HeV and NiV. Significant similarity exists between ferret 
and human lung physiology and morphology [50] and ferrets 
have been used previously for toxicology and biological 
safety assessment studies [51]. We have confirmed that fer-
rets are susceptible to NiV infection with disease developing 
6 to 10 days following oronasal administration of 500 to 
50,000 TCID50 (Bossart, K., Bingham, J. and Middleton, D., 
unpublished data). A lower dose of 50 TCID50 failed to pro-
duce infection as defined by fever, illness, detection of virus, 
viral antigen or viral genome, histopathological lesions or 
seroconversion. Infection first manifested as fever and this 
was followed by inappetance and severe depression. A mild 
increase in respiratory rate in some animals was attributable 
to fever with one ferret showing tremors and hindlimb 
weakness. Gross pathology included subcutaneous edema of 
the head, hemorrhagic lymphadenopathy of submandibular, 
retropharyngeal and sometimes visceral lymph nodes, nu-
merous diffuse pin-point hemorrhagic nodules scattered 
throughout the pulmonary parenchyma and petechial hemor-
rhages of the renal cortex. Histopathological lesions included 
focal necrotizing alveolitis, vasculitis, degeneration of 
glomerular tufts, and focal necrosis in a range of other tis-
sues, including lymph nodes, spleen, adrenal cortex, bladder 
and ovary. Lesions in each case were associated with signifi-
cant quantities of viral antigen, as determined by immuno-
histochemical staining (Fig. 1). Syncytial cells were also 
frequently present in lesions. NiV genome was detected in 
blood, brain, liver, testes, adrenal, kidney, lung, lymph node 
and spleen. These preliminary results are encouraging and 
indicate that the ferret may be another suitable model for 
human infection. 
  The golden hamster, cat and ferret are practical labora-
tory animal models that can be used to evaluate aspects of 
disease caused by either HeV or NiV, and each is more ame-
nable to therapeutic efficacy testing than large domestic 
animals particularly for these BSL-4 pathogens. In hamsters 
NiV-associated encephalitis was unique among the small 
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length of clinical course, where animals were kept until 
death occurred naturally [40]. In all other studies, most ani-
mals were euthanized before advanced disease onset (Table 
1). In summary, exploration and validation of such animal 
models is critical for the future exploration of therapeutic 
intervention strategies as is the development of non-human 
primate models for both HeV and NiV infection which has 
yet to be attempted in earnest. 
ANTIVIRAL THERAPEUTIC TARGETS 
  Although there are superb examples of effective antiviral 
drugs that target viral replication, such as the DNA chain-
terminators used in the treatment of various herpes viruses 
and the numerous drugs that interfere with the replication of 
human immunodeficiency virus type 1 (HIV-1) (reviewed in 
[52]), for the vast majority of human viral pathogens there is 
a vast shortage of effective therapies. Importantly, to date, 
only one antiviral drug has been utilized during a henipavi-
rus outbreak, ribavirin, which was first synthesized in1972 
[53]. It is perhaps the best known alternative drug therapy, 
exhibiting antiviral activity against a variety of mostly RNA 
viruses. Ribavirin is an accepted treatment for several viral 
infections including RSV, arenaviral hemorrhagic-fevers 
such as Lassa virus and some members of the family Bun-
yaviridae (reviewed in [54]). Because of its global availabil-
ity and broad antiviral properties it is often employed for the 
treatment of viral diseases under conditions where no other 
options are available except supportive care. During the NiV 
encephalitis outbreak in Malaysia, there was evidence that 
ribavirin exhibited some clinical benefit [54-56] with an ap-
parent 36% reduction in mortality with little evidence of 
serious side effects. Thus, ribavirin appears to be one avail-
able antiviral option; however, with fatality approaching 
75% in the most recent NiV outbreaks in Bangladesh and 
India, a more effective repertoire of antiviral agents is 
needed. 
  HeV and NiV are transmitted oranasally, spread systemi-
cally and infected individuals succumb to disease within 7 to 
10 days. Clinical and experimental data demonstrate that 
multiple organ systems are affected and that the lungs and 
brain are major sites of virus replication. Viremia has been 
documented in both clinical and experimental infections; 
however, the kinetics and duration vary. For both viruses, 
acute and late-onset encephalitis has been documented clini-
cally. The initial sites and duration of henipavirus replication 
upon infection are largely unknown, mainly due to a lack of 
extensive  in vivo experiments. Consequently, the optimal 
target and time frame for drug intervention are not known. 
Theoretically, therapeutics that target the mucosa should 
reduce viral loads in the lung. Intravenous agents should 
decrease viral loads and reduce systemic spread. Although 
targeting the CNS may prove difficult, a significant reduc-
tion in viral loads peripherally may enable the host to gener-
ate a protective immune response. 
 
Fig. (1). Histopathology and immunohistochemistry associated with NiV infection in ferrets. A: Severe necrotizing alveolitis and vasculitis 
with positive staining for NiV nucleoprotein antigen in blood vessel wall (long arrows) and syncytial cells (short arrows). B: Acute glomeru-
lar degeneration with associated NiV nucleoprotein antigen in ferret kidney. A syncytial cell (arrow) is visible along the inner membrane of 
Bowman's capsule. Immunohistochemistry, haematoxylin counterstain. Scale bar for all images = 50 μm. 
Table 2.   Effective Henipavirus Vaccines 
 
  Immunization Schedule  Adjuvant  Challenge: Dose and Route  Immune Correlates of Survival 
Vaccinia viruses encod-
ing NiV F or G 
(hamsters) 
2 subcutaneous doses 
(10
7 pfu per dose) 
1 month apart 
None  3 months post immunization, 
1000 pfu NiV intraperitoneally 
Viral load 
Antibodies (ELISA and SNT) 
Canarypox viruses en-
coding NiV F or G 
(pigs) 
2 intramuscular doses (10
8 
pfu per dose) 
14 days apart 
None 
29 days post immunization, 
2.5 x 10
5 pfu NiV intranasally 
Viral load 
Cytokine production 
Antibodies 
(ELISA, IFA and SNT) 
Recombinant HeV or 
NiV soluble G 
(cats) 
3 subcutaneous doses (100 
g per dose) 
14 days apart 
CSIRO triple 
adjuvant 
11 weeks post immunization, 
500 TCID50 NiV subcutaneously 
Viral load 
Antibodies (SNT) 19    The Open Virology Journal, 2007, Volume 1  Bossart et al. 
  To date, all novel henipavirus therapeutic agents that 
have been identified target and interfere with HeV and NiV 
virus entry and these candidates can be divided into two 
categories: those used for prevention of disease, including 
various vaccines, and those used for treatment post-exposure 
which includes antibodies, fusion inhibitors and soluble re-
ceptor molecules. The scope of this review will be limited to 
those agents tested using infectious HeV or NiV in vitro or 
in vivo. 
PREVENTION: VACCINE DEVELOPMENT 
  The use of safe and efficacious vaccines has been crucial 
to prevention strategies for several important viral pathogens 
in humans. Presently, there are some sixteen FDA-approved 
vaccines routinely used to prevent infection by virulent hu-
man pathogens and the majority comprise live-attenuated 
virus preparations (reviewed [57]). Although new reverse 
genetics systems have been developed for NiV [58], it is 
unlikely that a live-attenuated vaccine will be approved for 
any BSL4 virus including HeV and NiV. All successful hu-
man viral vaccines induce neutralizing antibodies that can 
cross-react with immunologically relevant strains of a virus 
[59]. Furthermore, neutralizing antibodies are the key vac-
cine-induced protective mechanisms in the case of some well 
known human paramyxoviruses such as mumps and MeV 
[60, 61]. For paramyxoviruses, it is the envelope glycopro-
teins that elicit the majority of neutralizing antibody in an 
infected host [3]. Indeed, for henipaviruses, it has been dem-
onstrated that immunization of animals with recombinant 
NiV and HeV F or G glycoproteins, either as a live vaccinia 
virus vector or purified protein preparation can elicit potent 
cross-reactive virus neutralizing humoral responses in ham-
sters and rabbits, respectively [62, 63]. 
  The first successful experimental henipavirus vaccine 
utilized recombinant vaccinia viruses that encoded NiV F or 
G glycoprotein. In these studies, vaccination protected 
against NiV challenge in golden hamsters and importantly, 
protection lasted five months post-challenge suggesting pro-
tection potentially from late-onset disease symptoms [62]. 
Although important for proof of principle, these recombinant 
viruses are not a viable human vaccine candidate due to the 
inherent risks of vaccinia virus vaccination. Poxvirus vectors 
have emerged as licensed veterinary vaccines as well as can-
didate vaccines for humans. Concerns about the safety of 
wild-type vaccinia virus have been addressed with the advent 
of attenuated poxviruses such as modified vaccinia virus 
Ankara (MVA), which is considered the vaccinia virus strain 
of choice for clinical investigation [64]. Although, recombi-
nant MVA expressing HeV F or G has been generated, nei-
ther has been tested as a vaccine candidate (Bossart, K. and 
Broder, C.; unpublished data). Other poxvirus vectors shown 
to be attenuated in humans, such as the avipoxviruses, have 
also been explored as live vaccine vectors (reviewed in [65, 
66]) and licensed feline, canine and equine canarypox virus-
based vaccines are commercially available [67]. Recently, 
recombinant canarypox virus-based vaccines encoding NiV 
F or G successfully protected pigs from NiV challenge [68]. 
Interestingly, neutralizing antibodies and cell mediated im-
munity were examined and the study suggested that G-
containing recombinant canarypox vaccines could elicit pro-
tective humoral and type 1 cell-mediated immune responses. 
Understanding and optimizing the immune response to heni-
paviruses represents a key aspect of human vaccine devel-
opment. Importantly, this was the first report of recombinant 
canarypox virus vaccines being used in pigs and represents 
significant progress towards a veterinary vaccine for NiV. 
Furthermore, if evaluated successfully in an independent 
animal model, recombinant NiV F- and G-containing ca-
narypox vaccines could potentially be used as human NiV 
vaccine candidates. 
  Recombinant subunit immunogens represent a viable 
avenue of vaccine development for the henipaviruses. These 
vaccines can be quickly implemented, are quite simple, and 
can be administered with no risk of infection. Recently, re-
combinant, soluble, oligomeric versions of the G glycopro-
tein of both HeV and NiV (sG) were generated as potential 
subunit vaccines [63]. Recombinant, purified sG prepara-
tions have been shown to be ideal immunogens that retain a 
number of important functional and antigenic properties in-
cluding the ability to bind virus receptor, block virus infec-
tion, and elicit a robust polyclonal neutralizing antibody re-
sponse in rabbits and mice [63]. The sG glycoprotein can 
also capture and isolate virus-specific neutralizing human 
monoclonal antibodies (mAbs) from naive recombinant li-
braries [69]. When HeV and NiV sG were used as subunit 
vaccines in a cat NiV challenge model, all animals were pro-
tected from disease [43]. The serum neutralization titers were 
on the order of 1:20,000 and represented the highest titers 
against henipaviruses obtained to date. The high neutralizing 
antibody titers and the absence of NiV genome in all vacci-
nated animals following challenge suggested that the sG 
subunit vaccines elicited sterilizing immunity. Unlike previ-
ous vaccines strategies, heterotypic protection was achieved 
where the attachment glycoprotein from HeV protected 
against challenge with NiV. If evaluated successfully in an 
additional animal model, these subunit vaccines may also 
represent viable human vaccine candidates. All of the poten-
tial vaccines discussed thus far are summarized in Table 2. 
  In order for a henipavirus vaccine to be considered for 
human use, not only does it need to be successful in two 
animal models, a natural route of infection should be used in 
Table 3.  Examples of Heterotypic Henipavirus Serum Titers 
 
Sera from Infected Individuals  Binding to NiV G  Binding to HeV G  Sera from sG Vaccinated Cats  SNT Titer NiV  SNT Titer HeV 
HeV human  1:16000  1:8000  HeV sG cat 1  1:20480  1:20480 
HeV horse  1:16000  1:32000  HeV sG cat 2  1:20480  1:20480 
NiV human  1:32000  1:2000  NiV sG cat 3  1:20480  1:1280 
NiV pig  1:8000  neg  NiV sG cat 4  1:20480  1:2560 
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protection studies, the mechanism and limits of protection 
should be elicited, and the highest standards should be used 
for reagents production to assure safety and success in hu-
man trials. Additionally, for HeV and NiV, we believe it 
would be ideal to have one vaccine that protects against both 
viruses. All of the above vaccine trials offer critical data to-
wards these goals, but further refinement of reagents and 
protocols are necessary. Firstly, the selection of adjuvant will 
be important in human use. Secondly, a correlation between 
vaccine dose and protection will need to be established to 
ensure that vaccine preparations induce protective immune 
responses well above sub-optimal levels. Correlations of 
immunity will also be critical, including antibody subclasses 
such as IgA, IgG and IgM and their location (serum vs mu-
cus membranes). Finally, it will be important to determine 
the role of cell-mediated type 1 immune responses in the 
strength and longevity of protective immunity. 
  To address these concerns, a new sG subunit vaccine trial 
has been initiated. HeV sG was chosen as the antigen be-
cause, based on previously established G-specific cross neu-
tralization titers [43, 70], it can elicit the best cross-reactive 
henipavirus immune response (see Table 3). Varying doses 
of sG were employed in hopes of correlating protection with 
vaccine dose. Additionally, small CpG DNA molecules were 
used as the adjuvant for several reasons. Recent studies have 
demonstrated that CpG molecules can elicit mucosal and 
systemic type 1 cell-mediated immune responses regardless 
of the route of vaccine delivery. Equally important, several 
CpG molecules have been approved by the FDA for use in 
humans and numerous others are in clinical trials. All vacci-
nated animals were challenged oronasally with 50,000 
TCID50 of a low passage NiV isolate. Preliminary pre-
challenge results are summarized in Table 4. As expected, 
different doses of sG induced varying levels of serum neu-
tralizing antibody, and titers were significantly lower to NiV 
as compared to HeV. Antigen-specific IgG and IgM were 
detected in all sera from all vaccinated animals, and sG-
specific IgA was present in serum from one high dose ani-
mal. Interestingly, HeV sG-specific IgA was detected in the 
mucosal washes from all vaccinated animals. Post-challenge 
titers and protection from disease are not yet known, how-
ever, the data generated in the current vaccine trial will be 
valuable for future development of a human henipavirus 
vaccine. 
POST-EXPOSURE THERAPEUTICS 
Antibodies 
  While the neutralizing antibodies elicited by a vaccine 
can be highly effective, purified neutralizing antibodies ad-
ministered passively to acutely infected individuals can be 
equally efficient. Passive antibody therapy is routinely used 
for prophylaxis against several important human pathogens 
including hepatitis B, varicella, RSV and rabies virus. With 
the advancement of mouse-human chimeric mAbs and the 
capability to ‘humanize’ murine mAbs, passive antibody 
therapy has become even more efficient. One such example 
includes a ‘humanized’ mAb to RSV F protein (Syna-
gis®/Palivizumab), a more cost-effective and highly sucess-
ful treatment compared to the original polyclonal product 
[71]. Passive therapy for NiV was first demonstrated using 
polyclonal hyper immune serum in hamsters [62]. Here, 
hamsters were administered anti-NiV F or anti-NiV G poly-
clonal sera prior to challenge and all animals survived sub-
sequent NiV challenge. In more recent studies, murine mAbs 
directed against NiV F or G were evaluated in lethal NiV 
challenge experiments in hamsters [72]. When mAbs were 
administered prior to and shortly after challenge all animals 
were protected. However, when administered 24 hours post-
challenge, only 50% of the animals survived. Together these 
data demonstrate that passive transfer is possible for NiV. 
Importantly, to be further developed as a post-exposure ther-
apy for human use, efficacy of this treatment needs to be 
increased beyond a 24 hour window, and murine mAbs may 
need to be converted to more humanized molecules. 
  A major advancement in antibody technology has been 
the development of the phage display platform of combinato-
rial antibody libraries [73] as well as domain and chain shuf-
fling methodologies to generate antibodies with new func-
tional properties [74]. Phage libraries encode antibodies in 
the form of single-chain variable region fragments (scFvs) or 
Fab’ fragments. Human phage display platforms are the most 
extensively used and this technology has been comple-
mented by innovative affinity maturation strategies to obtain 
high affinity reagents (reviewed [75]). These new techniques 
in human phage display platforms have been an enabling 
technology for the very rapid identification and isolation of 
specific mAbs, and have eliminated the time-consuming 
processes of immunization, hybridoma development and 
Table 4.  Antibody Profiles of sG Vaccinated Cats 
 
  HeV SNT Titer  NiV SNT Titer  sG-specific 
Serum IgG 
sG-specific 
Serum IgM 
sG-specific Serum IgA  HeV sG-Specific Mucosal IgA 
Control 1:32  <  1:2  -  -  -  - 
Control 1:16  <  1:2  -  -  -  - 
High dose  1:4096  1:512  +  +  +  + 
High dose  1:2048  1:256  +  +  -  + 
Medium dose  1:4096  1:512  +  +  -  + 
Medium dose  1:4096  1:256  +  +  -  + 
Low dose  1:1024  1:128  +  +  -  + 
Low dose  1:1024  1:32  +  +  -  + 
SNT = serum neutralization test; sG-specific = antibodies detected to both HeV and NiV sG. 21    The Open Virology Journal, 2007, Volume 1  Bossart et al. 
humanization techniques. Neutralizing human mAbs reactive 
to the G glycoprotein of HeV and NiV have been success-
fully identified, isolated, and characterized using these re-
combinant antibody techniques [69]. In particular, Fab’ 
fragment m102 had significant neutralizing activities against 
both henipaviruses and mapped to the receptor binding do-
main of HeV and NiV G [69, 70]. Subsequently, m102 was 
converted to a full length human IgG1 antibody, affinity 
maturated (m102.4) and evaluated in virus neutralization 
assays. The m102.4 human IgG antibody could completely 
neutralize both HeV and NiV at concentrations as low as 10 
μg/ml (Zhu, Z. and Bossart, K.; unpublished data). In light of 
its potency in vitro, its mechanism of neutralization and the 
fact that is a fully human antibody, m102.4 could provide a 
valuable post-exposure or post-infection therapeutic for dis-
ease caused by HeV or NiV in humans. Pharmacological 
assays are currently under development and will be dis-
cussed below. 
Fusion Inhibitory Peptides 
  There have been considerable advances in mechanistic 
models of how several viral envelope glycoproteins function 
in driving the membrane fusion reaction (reviewed in [76-
78]). A key component of many of these fusion glycopro-
teins is two -helical domains referred to as heptad repeats 
(HR) that are involved in the formation of a trimer-of-
hairpins structure [79, 80]. HR-1 is located proximal to the 
amino (N)-terminal fusion peptide and HR-2 precedes the 
transmembrane domain near the carboxyl (C)-terminus [79, 
81-83]. For many viral fusion glycoproteins the N-terminal 
HR-1 forms an interior, trimeric coiled-coil surrounded by 
three anti-parallel helices formed from HR-2 and the forma-
tion of this structure mediates and provides the necessary 
energy to drive viral-host cell membrane merger (reviewed 
in [84]). 
  Over the past decade, targeting the viral membrane fu-
sion process for antiviral drug development has received 
much attention, primarily lead by work on HIV-1 (reviewed 
in [85]). Importantly, the HIV-1 envelope derived peptide, 
enfuvirtide (Fuzeon™, formerly T-20), has been a clinical 
success [86, 87]. Enfuvirtide is a 36-amino acid peptide cor-
responding to a portion of the C-terminal HR-2 domain of 
the gp41 subunit of the envelope glycoprotein. Peptide se-
quences derived from F glycoprotein HR domains of several 
paramyxoviruses, including HeV and NiV have been shown 
to be potent inhibitors of fusion [88-93]. Moreover, HeV and 
NiV F glycoprotein HR domains have been shown to interact 
with each other and form the typical 6-helix coiled-coil bun-
dles [94]. 
  For the henipaviruses, second generation heptad-derived 
peptides were synthesized with chemical modifications of 
either the N- or C-terminus of the peptide by capping and/or 
“pegylation”, the coupling of polyethylene glycol (PEG) to 
proteins. Specific chemical modifications of the NiV F hep-
tad-derived peptide were chosen, especially pegylation, to 
help improve plasma half-life and thus enhance therapeutic 
success. Pegylation is currently considered one of the most 
successful techniques to prolong the residence time of pro-
tein drugs in the bloodstream [95-98]. Like their predeces-
sors, the new chemically modified heptad-derived peptides 
potently inhibited henipavirus infection in vitro in a dose-
dependent fashion [99]. The plasma half-life of these pep-
tides was recently evaluated in cats in vivo and was found to 
be unusually short (Crameri, G. and Broder, C., unpublished 
data), especially when compared to the half-life of Enfuvir-
tide in humans. As pure carnivores, cats have a unique me-
tabolism designed to convert protein into sugar and this fea-
ture may have played a role in the rapid clearance of peptides 
from the bloodstream. For these reasons the peptide plasma 
half-life is currently being reevaluated in another animal 
species, ferrets. Once pharmacological studies have been 
completed and adequate peptide plasma half-life has been 
demonstrated, these peptides will be administered in vivo to 
examine their efficacy in treatment of ongoing NiV-
mediated disease. It is hoped that, as was seen with enfuvir-
tide, the fusion inhibiting peptides might reduce viral load 
and or systemic spread in vivo. 
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Soluble Receptor Molecules 
  In addition to using virus-neutralizing human mAbs or 
peptides as a post-exposure therapeutic modality for HeV 
and NiV infection, a soluble virus receptor which binds G 
and prevents attachment of the virion to the host cell may 
also represent a feasible therapeutic strategy. It has been 
demonstrated that soluble ephrin-B2 ligand can block infec-
tious henipavirus infection in vitro [27] and more recently, it 
has been demonstrated that soluble ephrin-B2 ligand could 
block both ephrin-B2 and ephrin-B3 ligand mediated heni-
pavirus infections in vitro (Bossart, K. and Wang, L.; unpub-
lished data). Although only recently identified as a func-
tional receptor for the henipaviruses, the ligand ephrin-B2 
and its cellular receptor EphB4, have attracted much atten-
tion due to their roles in cancer biology [100, 101]. Cur-
rently, soluble versions of both molecules are being explored 
as possible therapeutic drugs for human cancer. Specifically, 
blocking this receptor/ligand interaction inhibits the end 
stage of tumor blood vessel formation and causes direct 
growth inhibition of certain cancers [33, 102]. Interestingly, 
EphB4 has no inhibitory effects on ephrin-B3 ligand medi-
ated henipavirus infection, only EphB3 a natural receptor for 
ephrin-B2 and ephrin-B3 ligands, was capable of blocking 
all henipavirus infections in vitro (Bossart, K. and Wang, L.; 
unpublished data). The potential passive therapeutic efficacy 
of soluble ephrin-B2 ligand or EphB3 protein in an animal 
model remains to be determined. However, their mechanism 
of action could be viewed as similar to that of a G glycopro-
tein-specific or receptor-specific antibody. A summary of all 
prevention and post-exposure henipavirus therapeutics is 
shown in Fig. (2). 
Pharmacology of Post-Exposure Therapeutics 
  A complete understanding of plasma half-life and toxic-
ity are required for the development of any human use thera-
peutic. The pharmacological properties of virus-specific hu-
man mAbs and heptad-derived peptides are currently being 
evaluated  in vivo, and we believe that soluble ephrin-B2 
ligand and EphB3 studies will commence in the not too dis-
tant future. To aid drug measurement ex vivo, new assays 
that exhibit extraordinary sensitivity have been developed. 
Differential henipavirus serology and neutralization assays 
using Bio-plex array systems were recently described [70]. 
These assays used HeV and NiV sG-coupled fluorescently-
labeled microspheres, test sera or soluble receptors and phy-
coerythrin-labeled detection molecules and binding results 
were reported as median fluorescent intensities. Although 
developed to detect host antibodies that interfered with re-
ceptor binding, these assays were easily adapted for measur-
ing therapeutics that bound the attachment glycoproteins of 
HeV and NiV. The sG coupled-microspheres have been used 
to detect ephrin-B2 ligand and G-specific human mAbs, with 
approximate sensitivities of 5 ng/ml and 250 pg/ml; respec-
tively (Bossart, K. unpublished data). Clearly, these assays 
will prove valuable for detecting soluble ephrin-B2 ligand in 
sera and are already being used to measure G-specific human 
mAbs in sera during plasma half-life experiments. Finally, 
another microsphere-based assay capable of measuring F-
specific heptad-derived peptides in sera has been developed. 
In this assay, microspheres coated with heptad-derived pep-
tide are detected using a peptide-specific polyclonal antibody 
and anti-rabbit-phycoerythrin molecules and results are re-
ported as median fluorescent intensities. When test sera are 
added, free peptide competes for antibody binding and thus 
decreased fluorescent signals are detected. Similar to the 
other microsphere assays, this new peptide assay has an ap-
proximate sensitivity of 5 ng/ml Examples of standard 
curves for all assays are shown in Fig. (3). The development 
of such assays will enable accurate measurement of each 
potential therapeutic agent ex vivo and set the stage for 
evaluating the efficacy of each in henipavirus animal chal-
lenge models. 
 
Fig. (3). Standard curves using new pharmacological assays for 
various post-exposure therapeutic agents. For each graph, median 
fluorescent intensity (M.F.I.) is shown on the Y-axis and concentra-
tion is shown on the X-axis. For panels A and B binding to soluble 
HeV G- and soluble NiV G-coupled microspheres are indicated by 
white and black bars, respectively. For panel C binding of antibody 
to peptide-coupled microspheres in the presence and absence of free 
peptide is indicated by black bars. A: Binding of recombinant hu-
man m102.4 IgG1 monoclonal antibody; B: Binding of recombinant 
soluble ephrin-B2 ligand; C: Competition by soluble heptad-
derived peptide. 
CONCLUDING REMARKS 
  The increased understanding of henipavirus pathogenesis 
has lead to the development of suitable animal models of 23    The Open Virology Journal, 2007, Volume 1  Bossart et al. 
disease and potential therapeutics. The successful vaccine 
candidates have been trialed in one animal model but still 
need to be evaluated in an independent animal model. Addi-
tionally, as discussed, while providing important proof of 
concept data, further understanding of protection mecha-
nisms and refinement of reagents will be critical if any vac-
cine candidate is to progress further. Most of the post-
exposure therapeutic agents have only been tested in vitro 
and will require in vivo half-life studies and disease preven-
tion efficacy studies in at least two animal models. The com-
plexities of such studies include optimizing drug delivery in 
vivo and site-specific targeting of post-exposure antivirals. 
Although many avenues of henipavirus therapeutic research 
have been successful, it will most likely take at least five to 
ten years before any therapeutic agent undergoes all neces-
sary testing, gains FDA approval and is used routinely dur-
ing an outbreak. 
  An understanding of the molecular biology of HeV and 
NiV has expanded rapidly in recent years. Although this re-
view has been limited to those agents tested against infec-
tious virus, numerous in vitro cell culture systems have been 
developed for examining various henipavirus gene-specific 
functions. Consequently, protein-based mechanisms, such as 
attachment and fusion, F cleavage, interferon interference 
and virus particle formation have been further elicited [103]. 
Importantly, these processes all represent targets for new 
antiviral drug development and both high throughput screen-
ing and specific inhibition assays are well underway. The 
construction of a NiV reverse genetics system [58], although 
unlikely to be used in vaccine trials, will significantly aid 
gene knock out studies using infectious clones and new 
therapeutic targets will most likely be identified. New thera-
peutic gene silencing techniques, such as small interfering 
RNA molecules, are also being developed for NiV. Charac-
terized genes are the current targets; however, new genome 
regions identified using reverse genetics also represent po-
tential sequence targets. The vast expansion of henipavirus 
molecular biology has underpinned new drug discovery; 
however, virus neutralization assays, drug characterization in 
vivo and efficacy studies still represent the most challenging 
phases of drug development for HeV and NiV, especially 
under BSL-4 restrictions. 
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